Vi-Mab do not cross-react with PRL

Posted on by

Front. Endocrinol., 29 April 2024 | Sec. Translational and Clinical Endocrinology | Volume 15 – 2024

The ELISA with the vasoinhibin monoclonal antibody (Vi-mab) was evaluated for cross-reactivity with prolactin (PRL) by measuring PRL alone and in the presence of various concentrations of recombinant vasoinhibin. The reactivity of PRL alone was at blank level, and it did not interfere with the detection of vasoinhibin (Vi) when measured in combination.

https://www.frontiersin.org/articles/10.3389/fendo.2024.1345996/full#supplementary-material

https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2024.1345996/full

https://davids-science.de/en/p/vasoinhibin-monoclonal-antibody-mouse-monoclonal-20-l